Buloxibutid

Buloxibutid
Clinical data
Other names	VP-01
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name butyl N-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate;
CAS Number	477775-14-7;
PubChem CID	9804984;
DrugBank	DB18038;
ChemSpider	7980744;
UNII	RC2V4W0EYC;
ChEMBL	ChEMBL189568;
Chemical and physical data
Formula	C23H29N3O4S2
Molar mass	475.62 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCOC(=O)NS(=O)(=O)C1=C(C=C(S1)CC(C)C)C2=CC=C(C=C2)CN3C=CN=C3;
	InChI InChI=1S/C23H29N3O4S2/c1-4-5-12-30-23(27)25-32(28,29)22-21(14-20(31-22)13-17(2)3)19-8-6-18(7-9-19)15-26-11-10-24-16-26/h6-11,14,16-17H,4-5,12-13,15H2,1-3H3,(H,25,27); Key:XTEOJPUYZWEXFI-UHFFFAOYSA-N;

Buloxibutid is an investigational new drug that is being evaluated to treat COVID-19 infections.^[1] It is an angiotensin II receptor type 2 agonist.^[2] The drug was discovered and developed by Professor Anders Hallberg and colleagues at the University of Uppsala. As at late 2024 it was on large scale trials for treatment of lung fibrosis following successful small-scale trials. Development is supported by investment from Sanofi.^[3]

References

^ "Buloxibutid - Vicore Pharma". AdisInsight. Springer Nature Switzerland AG.
^ Rein-Hedin E, Sjöberg F, Ganslandt C, Skoog J, Zachrisson H, Bengtsson T, et al. (February 2024). "Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist". Clinical and Translational Science. 17 (2): e13735. doi:10.1111/cts.13735. PMC 10859786. PMID 38344891.
^ Basic research led to drug candidates for fatal lung disease by Åsa Malmberg, Uppsala University news, 18 November 2024 https://www.uu.se/en/news/2024/2024-11-18-basic-research-led-to-drug-candidates-for-fatal-lung-disease

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.